Laminin-332 sustains chemoresistance and quiescence as part of the human hepatic cancer stem cell niche.

[1]  T. Roskams,et al.  Pathogenesis and prognosis of hepatocellular carcinoma at the cellular and molecular levels. , 2015, Clinics in liver disease.

[2]  N. Shikata,et al.  Influence of Rictor and Raptor Expression of mTOR Signaling on Long-Term Outcomes of Patients with Hepatocellular Carcinoma , 2015, Digestive Diseases and Sciences.

[3]  Philip Levy Ho,et al.  Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance , 2014, Nature.

[4]  N. Grabe,et al.  Aberrant self‐renewal and quiescence contribute to the aggressiveness of glioblastoma , 2014, The Journal of pathology.

[5]  G. Giannelli,et al.  Moving towards personalised therapy in patients with hepatocellular carcinoma: the role of the microenvironment , 2014, Gut.

[6]  S. Thorgeirsson,et al.  Targeting the mTOR pathway in hepatocellular carcinoma: current state and future trends. , 2014, Journal of hepatology.

[7]  G. Gores,et al.  Hepatocellular carcinoma: clinical frontiers and perspectives , 2014, Gut.

[8]  L. Ellis,et al.  Colon Cancer Cells Escape 5FU Chemotherapy-Induced Cell Death by Entering Stemness and Quiescence Associated with the c-Yes/YAP Axis , 2013, Clinical Cancer Research.

[9]  K. Boudjema,et al.  Molecular profiling of stroma identifies osteopontin as an independent predictor of poor prognosis in intrahepatic cholangiocarcinoma , 2013, Hepatology.

[10]  C. Blanpain,et al.  Unravelling cancer stem cell potential , 2013, Nature Reviews Cancer.

[11]  Jack A. Taylor,et al.  Keratin 19: a key role player in the invasion of human hepatocellular carcinomas , 2013, Gut.

[12]  S. Thorgeirsson,et al.  Modeling pathogenesis of primary liver cancer in lineage-specific mouse cell types. , 2013, Gastroenterology.

[13]  Tom H. Cheung,et al.  Molecular regulation of stem cell quiescence , 2013, Nature Reviews Molecular Cell Biology.

[14]  X. Wang,et al.  Cancer stem cells in the development of liver cancer. , 2013, The Journal of clinical investigation.

[15]  D. Sabatini,et al.  mTOR Signaling in Growth Control and Disease , 2012, Cell.

[16]  S. Thorgeirsson,et al.  Human hepatic cancer stem cells are characterized by common stemness traits and diverse oncogenic pathways , 2011, Hepatology.

[17]  P. Vigneri,et al.  Cancer Stem Cells and Chemosensitivity , 2011, Clinical Cancer Research.

[18]  S. Niclou,et al.  Critical appraisal of the side population assay in stem cell and cancer stem cell research. , 2011, Cell stem cell.

[19]  L. Vermeulen,et al.  Cancer stem cell niche: the place to be. , 2011, Cancer research.

[20]  H. Thomas,et al.  Remodelling of extracellular matrix is a requirement for the hepatic progenitor cell response , 2010, Gut.

[21]  K. Samuel,et al.  Characterisation of a stereotypical cellular and extracellular adult liver progenitor cell niche in rodents and diseased human liver , 2010, Gut.

[22]  J. Davie,et al.  H3 phosphorylation: dual role in mitosis and interphase. , 2009, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[23]  Jia Fan,et al.  Chemokine receptor CXCR4 expression in hepatocellular carcinoma patients increases the risk of bone metastases and poor survival , 2009, BMC Cancer.

[24]  S. Krauss,et al.  Characterization and functional analysis of a slow cycling stem cell-like subpopulation in pancreas adenocarcinoma , 2009, Clinical & Experimental Metastasis.

[25]  Shusen Zheng,et al.  Analysis of ABCG2 expression and side population identifies intrinsic drug efflux in the HCC cell line MHCC-97L and its modulation by Akt signaling. , 2008, Carcinogenesis.

[26]  A. Iwama,et al.  The polycomb gene product BMI1 contributes to the maintenance of tumor-initiating side population cells in hepatocellular carcinoma. , 2008, Cancer research.

[27]  E. Lesaffre,et al.  The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma. A possible progenitor cell origin , 2006, Histopathology.

[28]  Tetsuhiro Chiba,et al.  Side population purified from hepatocellular carcinoma cells harbors cancer stem cell–like properties , 2006, Hepatology.

[29]  T. Roskams.  Liver stem cells and their implication in hepatocellular and cholangiocarcinoma , 2006, Oncogene.

[30]  J. Gills,et al.  Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy. , 2005, Cancer research.

[31]  B. Davidson,et al.  Laminin-induced signaling in tumor cells. , 2005, Cancer letters.

[32]  A. Paradiso,et al.  Laminin-5 offsets the efficacy of gefitinib (‘Iressa’) in hepatocellular carcinoma cells , 2004, British Journal of Cancer.

[33]  T. Roskams,et al.  Progenitor cells in diseased human liver. , 2003, Seminars in liver disease.

[34]  G. Giannelli,et al.  Laminin-5 chains are expressed differentially in metastatic and nonmetastatic hepatocellular carcinoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.